ATE518886T1 - Verfahren zur änderung der bindungsspezifität von plasmaproteinen durch oxidations- reduktionsreaktionen - Google Patents

Verfahren zur änderung der bindungsspezifität von plasmaproteinen durch oxidations- reduktionsreaktionen

Info

Publication number
ATE518886T1
ATE518886T1 AT04754487T AT04754487T ATE518886T1 AT E518886 T1 ATE518886 T1 AT E518886T1 AT 04754487 T AT04754487 T AT 04754487T AT 04754487 T AT04754487 T AT 04754487T AT E518886 T1 ATE518886 T1 AT E518886T1
Authority
AT
Austria
Prior art keywords
binding specificity
oxidation
changing
plasma proteins
reduction reactions
Prior art date
Application number
AT04754487T
Other languages
English (en)
Inventor
John A Mcintyre
Original Assignee
Redox Reactive Reagents L L C
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Redox Reactive Reagents L L C filed Critical Redox Reactive Reagents L L C
Application granted granted Critical
Publication of ATE518886T1 publication Critical patent/ATE518886T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A61P25/10—Antiepileptics; Anticonvulsants for petit-mal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/5306—Improving reaction conditions, e.g. reduction of non-specific binding, promotion of specific binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/536—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase
    • G01N33/537—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase with separation of immune complex from unbound antigen or antibody
    • G01N33/5375—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase with separation of immune complex from unbound antigen or antibody by changing the physical or chemical properties of the medium or immunochemicals, e.g. temperature, density, pH, partitioning
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/81—Drug, bio-affecting and body treating compositions involving autoimmunity, allergy, immediate hypersensitivity, delayed hypersensitivity, immunosuppression, immunotolerance, or anergy
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/825—Pretreatment for removal of interfering factors from sample
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/868—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof involving autoimmunity, allergy, immediate hypersensitivity, delayed hypersensitivity, immunosuppression, or immunotolerance

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Rehabilitation Therapy (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
AT04754487T 2003-06-09 2004-06-09 Verfahren zur änderung der bindungsspezifität von plasmaproteinen durch oxidations- reduktionsreaktionen ATE518886T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US47660703P 2003-06-09 2003-06-09
PCT/US2004/017889 WO2004111608A2 (en) 2003-06-09 2004-06-09 Method of altering the binding specificity of plasma proteins by oxidation-reduction reactions

Publications (1)

Publication Number Publication Date
ATE518886T1 true ATE518886T1 (de) 2011-08-15

Family

ID=33551622

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04754487T ATE518886T1 (de) 2003-06-09 2004-06-09 Verfahren zur änderung der bindungsspezifität von plasmaproteinen durch oxidations- reduktionsreaktionen

Country Status (9)

Country Link
US (4) US7368542B2 (de)
EP (1) EP1631314B1 (de)
JP (1) JP4662557B2 (de)
CN (1) CN1832756A (de)
AT (1) ATE518886T1 (de)
AU (1) AU2004248155B2 (de)
BR (1) BRPI0411103B1 (de)
CA (1) CA2524325C (de)
WO (1) WO2004111608A2 (de)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4662557B2 (ja) 2003-06-09 2011-03-30 レドックス−リアクティブ リエイジェンツ リミテッド ライアビリティー カンパニー 酸化還元反応による血漿タンパク質の結合特異性の改変方法
US9557325B2 (en) 2003-06-09 2017-01-31 Redox-Reactive Reagents Llc Method of altering the binding specificity of proteins by oxidation-reduction reactions
US7892751B2 (en) 2003-06-09 2011-02-22 Redox-Reactive Reagents Llc Method of detecting or diagnosing of a neurodegenerative disease or condition
RU2007118954A (ru) * 2004-10-22 2008-11-27 Эмджен Инк. (Us) Способ рефолдинга рекомбинантных антител
KR101322247B1 (ko) * 2007-09-06 2013-10-25 삼성전자주식회사 진공청소기용 흡입브러시 및 그 높이조절방법
WO2009036209A2 (en) * 2007-09-14 2009-03-19 Amgen Inc. Homogeneous antibody populations
US7989596B2 (en) * 2007-09-19 2011-08-02 Redox-Reactive Reagents Llc Method of altering the binding specificity of monoclonal antibodies by oxidation-reduction reactions
JP5565607B2 (ja) 2009-07-15 2014-08-06 国立大学法人 東京大学 敗血症又は多臓器不全の予後診断方法及び予後診断用キット
WO2017120461A1 (en) 2016-01-08 2017-07-13 The Board Of Trustees Of The Leland Stanford Junior University Ccr3 modulation in the treatment of aging-associated impairments, and compositions for practicing the same
US20160208011A1 (en) 2010-01-28 2016-07-21 The Board Of Trustees Of The Leland Stanford Junior University Ccr3 modulation in the treatment of aging-associated impairments, and compositions for practicing the same
WO2011094535A2 (en) * 2010-01-28 2011-08-04 The Board Of Trustees Of The Leland Stanford Junior University Biomarkers of aging for detection and treatment of disorders
US9161968B2 (en) 2011-04-08 2015-10-20 The Board Of Trustees Of The Leland Stanford Junior University Methods of neuroprotection involving macrophage colony stimulating factor receptor agonists
WO2013154709A1 (en) 2012-04-13 2013-10-17 Diabetomics, Llc Maternal biomarkers for gestational diabetes
SG11201509595PA (en) 2013-05-28 2015-12-30 Dcb Usa Llc Antibody locker for the inactivation of protein drug
WO2015088915A1 (en) 2013-12-09 2015-06-18 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for treating aging-associated conditions
US10905779B2 (en) 2013-12-09 2021-02-02 The Board Of Trustees Of The Leland Stanford Junior University Methods for screening human blood products comprising plasma using immunocompromised rodent models
KR20220062668A (ko) 2015-06-15 2022-05-17 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 노화와 연관된 질환을 치료하기 위한 방법 및 조성물
KR101933920B1 (ko) 2016-09-22 2018-12-31 아주대학교 산학협력단 액상 플라즈마를 이용한 비만의 예방 또는 치료 방법
KR20180032489A (ko) * 2016-09-22 2018-03-30 아주대학교산학협력단 액상 플라즈마를 이용한 건선의 예방 또는 치료 방법
US11583689B2 (en) * 2016-09-22 2023-02-21 Ajou University Industry-Academic Cooperation Foundation Composition for atopy or psoriasis treatment comprising liquid type plasma
KR20180032490A (ko) * 2016-09-22 2018-03-30 아주대학교산학협력단 액상 플라즈마를 이용한 아토피성 피부염의 예방 또는 치료 방법
CA3042276A1 (en) 2016-12-09 2018-06-14 Seattle Genetics, Inc. Bivalent antibodies masked by coiled coils
KR102120552B1 (ko) 2017-09-18 2020-06-08 아주대학교산학협력단 액상 플라즈마를 포함하는 피부 진정용 조성물
CR20210521A (es) * 2019-04-18 2022-04-01 Janssen Biotech Inc Glicoproteínas saliladas
TR202016418A2 (tr) * 2020-10-14 2022-04-21 Tunç Serkan Kan plazmasinin üzeri̇nden elektri̇k akiminin geçi̇ri̇lmesi̇yle i̇çeri̇si̇nde ölü bakteri̇, parazi̇t vi̇rüs vb. kalintilarin oluştuğu yeni̇ plazmanin canli vücuduna serum olarak veri̇lmesi̇yle bağişiklik geli̇şti̇rme yöntemi̇

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4632980A (en) * 1985-04-03 1986-12-30 Immunologics Ozone decontamination of blood and blood products
US4703001A (en) 1985-10-23 1987-10-27 Synbiotics, Corporation Immunoassay for the detection of serum analytes using pH dependent chastropic acids
US4950612A (en) 1987-12-16 1990-08-21 Microgenics Corporation Peroxy acid pretreatment in vitamin B12 assay
ES2054877T3 (es) * 1988-02-22 1994-08-16 Fina Research Procedimiento catalitico de una etapa para la conversion directa de polisacaridos a alcoholes polihidricos.
US5061790A (en) * 1989-07-10 1991-10-29 Molecular Diagnostics, Inc. Oxidative denaturation of protein analytes
US5980954A (en) 1992-02-07 1999-11-09 Vasogen Ireland Limited Treatment of autoimmune diseases
US6660267B1 (en) * 1992-12-21 2003-12-09 Promega Corporation Prevention and treatment of sepsis
AU703814B2 (en) * 1995-12-04 1999-04-01 Wyeth Antioxidant
US5880954A (en) * 1995-12-04 1999-03-09 Thomson; Robert Continous real time safety-related control system
US5939394A (en) * 1996-01-18 1999-08-17 Fleming & Company Methods and compositions for the prevention and treatment of immunological disorders, inflammatory diseases and infections
FR2794461B1 (fr) * 1999-06-07 2004-01-23 Lab Francais Du Fractionnement Procede de preparation de nouvelles fractions d'ig humaines possedant une activite immunomodulatrice
FR2822238B1 (fr) * 2001-03-16 2003-08-29 Gemac Methode et trousse pour le suivi des maladies neurodegeneratives
US20040101909A1 (en) * 2002-08-20 2004-05-27 Hema-Quebec, 2535 Boul. Laurier, Ste-Foy, Quebec, Canada G1V 4M3 Purification of polyreactive autoantibodies and uses thereof
US9557325B2 (en) * 2003-06-09 2017-01-31 Redox-Reactive Reagents Llc Method of altering the binding specificity of proteins by oxidation-reduction reactions
JP4662557B2 (ja) 2003-06-09 2011-03-30 レドックス−リアクティブ リエイジェンツ リミテッド ライアビリティー カンパニー 酸化還元反応による血漿タンパク質の結合特異性の改変方法

Also Published As

Publication number Publication date
US20050101016A1 (en) 2005-05-12
US20080280281A1 (en) 2008-11-13
JP4662557B2 (ja) 2011-03-30
CN1832756A (zh) 2006-09-13
US20160046695A1 (en) 2016-02-18
US8334146B2 (en) 2012-12-18
EP1631314A2 (de) 2006-03-08
US20130109838A1 (en) 2013-05-02
WO2004111608A3 (en) 2005-04-07
EP1631314B1 (de) 2011-08-03
AU2004248155B2 (en) 2008-10-23
JP2006526027A (ja) 2006-11-16
CA2524325C (en) 2017-08-01
US7368542B2 (en) 2008-05-06
US10072068B2 (en) 2018-09-11
BRPI0411103A (pt) 2006-07-18
WO2004111608A2 (en) 2004-12-23
EP1631314A4 (de) 2006-08-16
US9169317B2 (en) 2015-10-27
WO2004111608A8 (en) 2005-12-29
CA2524325A1 (en) 2004-12-23
BRPI0411103B1 (pt) 2019-01-15
AU2004248155A1 (en) 2004-12-23

Similar Documents

Publication Publication Date Title
ATE518886T1 (de) Verfahren zur änderung der bindungsspezifität von plasmaproteinen durch oxidations- reduktionsreaktionen
CA2602635C (en) Method of altering the binding specificity of proteins by oxidation-reduction reactions
ATE404695T1 (de) Einfache katalytische dna-biosensoren für ionen auf grundlage von farbveränderungen
DE60326012D1 (de) Verfahren zur Konzentration von Proteinen
DE50102926D1 (de) Verfahren zur oxidation von kohlenwasserstoffen
NO20054790L (no) Anvendelse av B7-113 som et immunoregulatorisk middel
DE69800630D1 (de) Chip zur elektroforetischen Trennung von Molekülen und Verfahren zur Verwendung desselben
DE60007304D1 (de) Verfahren zur kryopräservierung von blutgefässen durch glasbildung
DE60239141D1 (de) Vorrichtung und verfahren zur reinigung von flüssigkeiten
DE602004012127D1 (de) Kommunikationsendgerät und verfahren zur zeitsteuerung der erkennung von kenngrössen des kommunikationsmediums
FR2841796B1 (fr) Traitement d'effluents associant separation solide/liquide et champs electriques pulses
ATA11042002A (de) Verfahren zur simulation des fahrverhaltens von fahrzeugen
DE60224275D1 (de) Moleküle und verfahren zur inhibierung der freisetzung von kim-1
DE60313870D1 (de) Gewinnung von plasmiden in einem wässrigen zweiphasensystem
ATE468413T1 (de) Verfahren zur extraktion von platinmetallen
DE60130661D1 (de) Verwendung der 13-cis retinsäure zur behandlung von emphysemen
DE60319369D1 (de) Nukleinsäuren, polypeptide und verfahren zur modulierung von apoptosis
ATE489478T1 (de) Nukleinsäuren, polypeptide und verfahren zur apoptosemodulation
DE60308716D1 (de) Verfahren zur isoelektrischen auftrennung mittels ph-wert-voreinstellung
ATE345340T1 (de) N-substituierte-1h-indol-5-propansäure verbindungen als ppar-agonisten zur behandlung von diabetis
ATE221657T1 (de) Entstörung durch rheumafaktoren
DE50204680D1 (de) Verfahren zur detektion von nukleinsäuremolekülen
DE60029429D1 (de) Verfahren und zusammensetzungen zur überwachung der modifikation von natürlichen bindungspartners
ATE452984T1 (de) Verfahren und zusammensetzungen zur extraktion von proteinen aus zellen
ATE402948T1 (de) Verfahren zur aufreinigung eines nichtimmunoglobulinproteins, das eine immunoglobulinähnliche (ig-like) domäne enthält

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties